# Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

> **NCT06888674** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **BIOLOGICAL:** individualized anti-tumor new antigen iNeo-Vac-R01 injection
- **DRUG:** Gemcitabine + Capecitabine
- **DRUG:** Sintilimab injection

## Key facts

- **NCT ID:** NCT06888674
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888674, "Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06888674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*